Chobani's Yogurt Rebels: FDA Permits Low-Fat Rule-Benders
Published Date: 6/18/2025
Notice
Summary
The FDA is letting Chobani keep testing new kinds of yogurt that don’t follow the usual rules, using ultrafiltered milk to make lower-fat options. This temporary permit extension helps Chobani see if people like these yogurts and gather info to possibly change the official yogurt rules. Other companies can join the fun and test their own unique yogurt products too!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Chobani Allowed To Market-Test Yogurt
The FDA amended and extended a temporary permit allowing Chobani, LLC to market test yogurt that deviates from the yogurt standard of identity and from 21 CFR 130.10 by using ultrafiltered nonfat milk as a basic dairy ingredient. The extension lets Chobani continue to evaluate commercial viability and collect consumer acceptance data to support a petition to amend the yogurt standard.
Other Firms Invited To Join Market Test
The FDA invited other interested parties to participate in the market test that permits yogurt products deviating from the standard of identity using ultrafiltered nonfat milk. Interested manufacturers can join the market test to evaluate commercial viability and collect consumer acceptance data in support of potential petitions to amend the yogurt standard.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19654, Naveed Aslam: Final Debarment Order
The FDA has permanently banned Dr. Naveed Aslam from working with any drug companies because he was convicted of a serious crime related to drug regulations. He didn’t respond to the FDA’s notice or ask for a hearing, so the ban started on September 25, 2026. Dr. Aslam can apply to end this ban anytime, but it won’t be easy or quick.
2026-19660, Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments
The FDA is gearing up to renew the Biosimilar User Fee Act, which helps fund the review of biosimilar drug applications. This affects drug makers and the public by ensuring faster, smoother approval processes from 2028 to 2032. They’re hosting a public meeting on October 26, 2026, and want your comments by November 25, 2026, to shape the future of this important program.
Previous / Next Documents
Previous: 2025-11205, Certain Frozen Fish Fillets From the Socialist Republic of Vietnam: Final Results and Partial Rescission of Administrative Review; 2022-2023
The U.S. checked prices on frozen fish fillets from Vietnam for August 2022 to July 2023 and found that Bien Dong Seafood didn’t sell below fair prices. Six other Vietnamese seafood companies earned special status, meaning they’re treated separately in trade reviews. Also, the review for the rest of Vietnam’s seafood exporters was canceled, so no extra duties or changes will hit them now.
Next: 2025-11209, Cheese Products Deviating From Standard of Identity; Temporary Permit for Market Testing
The FDA is letting Bongards' Creameries keep testing a new kind of cheese that uses olive oil to stop slices from sticking together. This temporary permit is extended so they can see if people like it and if it can be sold more widely. Other cheese makers can join in the fun and test their own versions too!